LBA11 Neoadjuvant toripalimab plus lenvatinib and GEMOX in resectable, high-risk intrahepatic cholangiocarcinoma: A randomized, multicenter, open-label phase II-III clinical trial
Guobang Shi(Fudan University), Jian Zou(Bioscience Research), Wen Yang(Chinese PLA General Hospital), YU Zhong-he(Qingdao University), Qing Gao(Tianjin University of Traditional Chinese Medicine), Rui Dong(Air Force Medical University), Xiao Liang(Convalife (China)), Jun Lü(Jiangsu Province Hospital), Q. Ye(Fudan University), Shuang–Jian Qiu(Fudan University), Xudong Li, Kai Wang(Michigan United), Fang Liu(Peking University), Jing Zhang(Shanghai Jiao Tong University), Jing Fan(Xijing Hospital), Fanrong Liang(Sichuan Provincial Department of Education), Yinghua Ji(First Affiliated Hospital of Xinxiang Medical University), Wenlong Zhai(Zhengzhou University), X M Huang(Fudan University), Jian Zhou(Shandong University)
Cited by 2
Related Papers
The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
|Proceedings of the National Academy of Sciences|2019|865
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652